What it is

HDAP2 is described in the literature as a mitochondria-targeted aromatic peptide designed to support mitochondrial membrane integrity.

Based on the available public abstract-level information, HDAP2 is being explored as a neuroprotective candidate in injury contexts where mitochondrial loss/dysfunction is an early driver of degeneration.

Why people care about it

In many neurodegenerative and neurotrauma scenarios, mitochondria are not just bystanders. When axons lose mitochondrial capacity, the downstream failure cascade can be hard to stop.

Peptides that can reach mitochondria in relevant tissues (and do so with tolerable systemic dosing) are therefore of broad interest, especially for CNS projection neurons.

What we know vs what we do not know

What we know:

HDAP2 has been tested in at least one mouse optic nerve injury model with structural neuroprotection readouts.
Systemic dosing has been reported to reach retinal layers (blood-retinal barrier penetration in that model).

What we do not know:

Human pharmacokinetics, dose feasibility, and safety profile.
Whether benefits generalize across disease models (for example chronic glaucoma vs acute crush injury).
Whether there is a validated molecular target or whether effects are best framed as membrane/mitochondria stabilization.

Latest updates

2026-03-27 (Neuroscience): In a mouse optic nerve crush model, daily systemic HDAP2 treatment was reported to reduce mitochondrial loss in injured optic nerve axons and improve retinal ganglion cell survival versus saline.
- https://pubmed.ncbi.nlm.nih.gov/41633465/ (doi:10.1016/j.neuroscience.2026.01.045)

Safety reality

HDAP2 is not an approved drug. Any non-regulated product claiming to be HDAP2 should be treated as high risk due to identity, purity, formulation, and contamination uncertainties.

References

MacNeil MA, et al. The mitochondria-targeted peptide HDAP2 reduces mitochondrial loss and retinal ganglion cell degeneration after optic nerve injury. Neuroscience. (2026). https://pubmed.ncbi.nlm.nih.gov/41633465/ doi:10.1016/j.neuroscience.2026.01.045